TP53 and myelodysplastic syndrome: Mutations in the TP53 gene in MDS patients are associated with generally unfavorable outcomes, aggressive disease course, higher risk of transformation to AML, shorter overall survival (OS), and resistance to lenalidomide treatment [17,37,51,59].